Nkarta (NKTX) Return on Capital Employed (2020 - 2026)
Nkarta's (NKTX) quarterly Return on Capital Employed came in at 31.44% in Q1 2026, down 318.0% year-on-year from 14.42% in Q1 2025, and down 1.4% quarter-over-quarter from 31.01% in Q4 2025.
Nkarta (NKTX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Nkarta's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 31.44% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 318.0% year-over-year to 31.44% in Q1 2026; TTM through Mar 2026 was 31.44%, a 318.0% decrease from a year earlier, with the FY2025 full-year figure at 28.34%, up 210.0% from the prior year.
- Return on Capital Employed fell to 31.44% in Q1 2026 per NKTX's latest filing, from 31.01% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 22.39% in Q3 2022 and bottomed at 35.67% in Q4 2023.
- The 5-year median for Return on Capital Employed is 28.93% (2023), against an average of 28.77%.
- Across the five-year window, Return on Capital Employed tumbled 1421 bps in 2022 and soared 996 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 25.51% in 2022, then plunged by 40 bps to 35.67% in 2023, then gained by 28 bps to 25.76% in 2024, then retreated by 20 bps to 31.01% in 2025, then fell by 1 bps to 31.44% in 2026.
- Per Business Quant, the three latest NKTX Return on Capital Employed figures stand at 31.44% (Q1 2026), 31.01% (Q4 2025), and 29.12% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Nkarta | 170.79 Mn | 170.79 Mn | - | -31.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.44% |
| Dec 31, 2025 | -31.01% |
| Sep 30, 2025 | -29.12% |
| Jun 30, 2025 | -29.16% |
| Mar 31, 2025 | -28.26% |
| Dec 31, 2024 | -25.76% |
| Sep 30, 2024 | -24.67% |
| Jun 30, 2024 | -22.76% |
| Mar 31, 2024 | -28.55% |
| Dec 31, 2023 | -35.67% |
| Sep 30, 2023 | -34.57% |
| Jun 30, 2023 | -32.71% |
| Mar 31, 2023 | -28.93% |
| Dec 31, 2022 | -25.51% |
| Sep 30, 2022 | -22.39% |
| Jun 30, 2022 | -25.28% |
| Mar 31, 2022 | -33.32% |
| Dec 31, 2021 | -31.98% |
| Sep 30, 2021 | -28.24% |
| Jun 30, 2021 | -23.72% |